Literature DB >> 11061621

Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.

A J Gelderblom1, W J Loos, M J de Jonge, A Sparreboom, A S Planting, M E van der Burg, E Brouwer, C Verheij, L Ouwens, S Hearn, J Verweij.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11061621     DOI： 10.1023/a:1008396414915

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

Authors:  Lot A Devriese; Petronella Els O Witteveen; Marja Mergui-Roelvink; Deborah A Smith; Lionel D Lewis; David S Mendelson; Yung-Jue Bang; Hyun Choel Chung; Mohammed M Dar; Alwin D R Huitema; Jos H Beijnen; Emile E Voest; Jan H M Schellens
Journal:  Br J Clin Pharmacol       Date:  2015-05-20       Impact factor: 4.335

2.  Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.

Authors:  H Gelderblom; A Sparreboom; M J de Jonge; W J Loos; E Wilms; M A Mantel; B Hennis; I Camlett; J Verweij; M E van der Burg
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.